Estrogen and Cyproterone Acetate Combination-Induced Autoimmune Hepatitis

Kaçar, Sabite; Akdoğan, Meral; Koşar, Y.; Parlak, Erkan; Şaşmaz, Nurgül; Oğuz, Perihan; Aydog, Gulden

doi:10.1097/00004836-200207000-00023

Cited by 22 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there are no other published case reports of thrombocytopaenia for this or other oral contraceptives, and thrombocytopaenia is not mentioned as a side effect in the US or German prescribing information. Autoimmune diseases following intake of oral contraceptives have only very rarely been described [43,44]. The observed increased risk should therefore be interpreted with caution and may be a statistical artefact.…”

Section: Discussionmentioning

confidence: 99%

Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study

Garbe

Andersohn

Bronder

et al. 2011

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study

Garbe

Andersohn

Bronder

et al. 2011

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…In a study, using 50 Lg of ethinyloestradiol50 mg of cyproterone acetate daily, 50% of the women showed improvement, with approximately 30% having complete remission for 18 months. 55 Another report showed clinical control using 100 mgd of cyproterone acetate in 4 women with long-standing HS; 56 unfortunately this drug is not available in the US owing to its potential hepatotoxicity [57][58][59] and theoretic concerns regarding feminization of male fetuses. 60,61 Data are lacking on the use of other oral contraceptives in HS, and the rationale for their use is largely based on anecdotal reports and clinical data confirming that oral contraceptives are useful in the treatment of acne.…”

Section: Antibiotic Treatmentmentioning

confidence: 99%

Painful Hidradenitis Suppurativa

Smith

Chao

Teitelbaum

2010

The Clinical Journal of Pain

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronically relapsing skin disorder characterized by recurring inflammatory lesion in hair and apocrine gland-bearing skin creases in the axilla; groin or perineum, buttocks, and/or breast. HS may lead to painful eruptions and malodorous discharge significantly detracting from quality of life. HS causes a high degree of morbidity with the highest scores obtained for the level of pain caused by the disease. The majority of patients rated their pain on a Numerical Rating Scale-11 ranging from 4/10 to 10/10 and described it at various times as hot, burning, pressure, stretching, cutting, sharp, taut, splitting, gnawing, pressing, sore, throbbing, and aching. Despite the severe pain associated with this disease, HS has been essentially ignored in the pain medicine literature. It is hoped that greater understanding of the diagnosis, pathophysiology, and potential treatment options available for patients with HS, may help put pain specialists in a better position to contribute to the overall care of patients with significantly painful HS. This article reviews HS and pain. Potential mechanisms of modulating nociceptive processes in the skin are presented. A greater understanding of the diagnosis, pathophysiology, and potential treatment options for HS patients may help providers to be better able to contribute to care of patients with painful hidradenitis suppurativa.

show abstract

“…Only one poorly documented case of AIH induced by CPA and ethinylestradiol combination therapy had been reported in a 17‐year‐old girl treated for hirsutism, who failed to achieve ALT normalization during treatment and after corticosteroid therapy. Liver histology in this patient showed cirrhosis associated with ductular proliferation, without evidence of autoimmune disease .…”

Section: Discussionmentioning

confidence: 99%